Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

This study was a multicenter, randomized, open, single-dose, two-cycle, two-cross-dosing human bioequivalence trial designed to evaluate the bioequivalence of tested and reference preparations in breast cancer subjects.

Trial Details

NCT ID
NCT06765590
Phase
NA
Sponsor
Sichuan Huiyu Pharmaceutical Co., Ltd
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • T, 260 mg/m2, paclitaxel for injection (albumin-bound)
  • R, 260 mg/m2, paclitaxel for injection (albumin bound).
Locations (sample)
  • Luoyang, Henan, China|34.67345,112.43684

Key Eligibility Criteria

  • Subjects voluntarily participate in the study and sign the informed consent forms (ICFs);
  • Patients with breast cancer confirmed by histopathology and/or cytology who meet one of the following conditions: ① with metastatic breast cancer t…
  • Aged 18-75 years old (both inclusive), males or females; body mass index (BMI) ≥17 (BMI = weight (kg)/height (m2));
  • The ECOG score is 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →